Yahoo Web Search

Search results

1. • 

     Moderna expects CDC to view its RSV vaccine as equal to rival shots

     Reuters· 8 hours ago

     , opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...

2. • 

     mRNA Vaccines: Not Just for COVID Soon?

     Medscape· 17 hours ago

     To date, mRNA vaccines have had their largest global presence in combating the COVID-19 pandemic. Intensive research is underway on many other potential...

3. • 

     High-risk patients with COVID symptoms should use PCR rather than rapid tests, study suggests

     Center for Infectious Disease Research and Policy· 5 hours ago

     Study findings that reveal a sensitivity of 47% for COVID-19 rapid antigen tests (RATs) compared...

4. • 

     Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

     Zacks via Yahoo Finance· 7 hours ago

     Year to date, shares of LGND have registered breakeven growth. Earnings of Ligand Pharmaceuticals...

5. • 

     WHO COVID vaccine advisers recommend switch to JN.1 strain

     Center for Infectious Disease Research and Policy· 3 days ago

     In a statement, the experts note that the XBB lineage has been displaced by JN.1 and said that, over...

6. • Nonprofit group Louisiana Families for Vaccines voice concerns over proposed bills

     WBRZ 2 Baton Rouge· 1 day ago

     The nonprofit group Louisiana Families for Vaccines is hoping six of the 13 proposed bills about COVID and vaccines will not become law ...

7. • Viral post mistakes aluminum guidelines on IV feeding for vaccine limit | Fact check

     USA TODAY via Yahoo News· 2 days ago

     ...Taison Bell, Jan. 3, Email exchange with USA TODAY CDC, reviewed Sept. 27, 2022, Adjuvants and Vaccines Electronic Code of Federal Regulations, accessed April...Parenteral Nutrition: Aluminum Content and Labeling Recommendations Vaccine, Nov. 28, 2011, Updated aluminum pharmacokinetics following...

8. • Moderna to seek parity for RSV shot (NASDAQ:MRNA)

     Seeking Alpha· 4 hours ago

     Moderna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.

9. • 

     Avian Flu Threat Still Low and Vaccine Measures Are Ready

     Medscape· 7 days ago

     "The risk to the general public remains low," said Vivien Dugan, PhD, director of the Influenza...